Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

VICTORIA (NCT05192642), is an exact-matching study comparing the outcomes of patients with TRK fusion cancer treated with larotrectinib in 3 clinical trials (NCT02122913, NCT02576431, NCT02637687) to patients treated with non-TRK inhibitor therapies in the real-world (RW) setting.

Outcomes of Larotrectinib Compared With Real-World Data From Non-TRK Inhibitor Therapies in Patients With TRK Fusion Cancer: VICTORIA Study